# Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma

> **NCT04396860** · PHASE2,PHASE3 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 159 (actual)

## Conditions studied

- Gliosarcoma
- MGMT-Unmethylated Glioblastoma

## Interventions

- **PROCEDURE:** Contrast-enhanced Magnetic Resonance Imaging
- **BIOLOGICAL:** Ipilimumab
- **BIOLOGICAL:** Nivolumab
- **DEVICE:** NovoTTF-100A Device
- **OTHER:** Quality-of-Life Assessment
- **OTHER:** Questionnaire Administration
- **RADIATION:** Radiation Therapy
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT04396860
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-01
- **Primary completion:** 2023-01-13
- **Final completion:** 2025-12-23
- **Target enrollment:** 159 (ACTUAL)
- **Last updated:** 2026-04-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04396860

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04396860, "Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04396860. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*